KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Equity Ratio (2016 - 2026)

Pacific Biosciences Of California has reported Equity Ratio over the past 16 years, most recently at 0.01 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 98.3% year-over-year to 0.01; the TTM value through Dec 2025 reached 0.01, down 98.3%, while the annual FY2025 figure was 0.01, 98.3% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.01 at Pacific Biosciences Of California, down from 0.04 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.4 in Q3 2023 and troughed at 0.01 in Q4 2025.
  • A 5-year average of 0.28 and a median of 0.34 in 2022 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: skyrocketed 75.33% in 2022 and later tumbled 98.3% in 2025.
  • Year by year, Equity Ratio stood at 0.39 in 2021, then fell by 19.17% to 0.32 in 2022, then rose by 26.09% to 0.4 in 2023, then grew by 0.06% to 0.4 in 2024, then tumbled by 98.3% to 0.01 in 2025.
  • Business Quant data shows Equity Ratio for PACB at 0.01 in Q4 2025, 0.04 in Q3 2025, and 0.07 in Q2 2025.